Journal of Cardiac Failure
Volume 12, Issue 6 , Pages 473-478 , August 2006

The Effect of Statins in Heart Failure: Beyond its Cholesterol-Lowering Effect

  • Kizhake C. Kurian, MD

      Affiliations

    • From the Division of Cardiology, University of Florida Health Science Center-Jacksonville, Jacksonville, Florida
    • Corresponding Author InformationReprint requests: K. C. Kurian, MD, University of Florida Health Science Center-Jacksonville, Division of Cardiology, 655 W 8th Street, Jacksonville, FL 32223.
    • ,
  • Prithviraj Rai, MD

      Affiliations

    • From the Division of Cardiology, University of Florida Health Science Center-Jacksonville, Jacksonville, Florida
    • ,
  • Sunder Sankaran, MD

      Affiliations

    • University of Michigan Medical Center, Ann Arbor, Michigan
    • ,
  • Binu Jacob, MD

      Affiliations

    • From the Division of Cardiology, University of Florida Health Science Center-Jacksonville, Jacksonville, Florida
    • ,
  • Jun Chiong, MD

      Affiliations

    • From the Division of Cardiology, University of Florida Health Science Center-Jacksonville, Jacksonville, Florida
    • ,
  • Alan B. Miller, MD, FACC

      Affiliations

    • From the Division of Cardiology, University of Florida Health Science Center-Jacksonville, Jacksonville, Florida

Received 21 December 2005 ,Revised 29 January 2006 ,Accepted 3 February 2006.

References 

  1. Dei Cas L, Metra M, Nodari S, Dei Cas A, Gheorghiade M. Prevention and management of chronic heart failure in patients at risk. Am J Cardiol. 2003;91:10F–17F
  2. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult—summary article. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46:1116–1143
  3. Inoue I, Goto S, Mizotani K, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci. 2000;67:863–876
  4. Bohm M, Hjalmarson A, Kjekshus J, Laufs U, McMurray J, van Veldhuisen DJ. Heart failure and statins—why do we need a clinical trial?. Z Kardiol. 2005;94:223–230
  5. Reddy R, Chahoud G, Mehta JL. Modulation of cardiovascular remodeling with statins: fact or fiction?. Curr Vasc Pharmacol. 2005;3:69–79
  6. Ichiki T, Takeda K, Tokunou T, et al. Down regulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001;21:1896–1901
  7. Hasegawa H, Yamamoto R, Takano H, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol. 2003;35:953–960
  8. Clerk A, Sugden PH. Small guanine nucleotide-binding proteins and myocardial hypertrophy. Circ Res. 2000;86:1019–1023
  9. Dechend R, Fiebeler A, Park JK, et al. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation. 2001;104:576–581
  10. Mital S, Liao JK. Statins and the myocardium. Semin Vasc Med. 2004;4:377–384
  11. Kumar D, Jugdutt BI. Apoptosis and oxidants in the heart. J Lab Clin Med. 2003;142:288–297
  12. Von Haehling S, Anker SD, Bassenge E. Statins and the role of nitric oxide in chronic heart failure. Heart Fail Rev. 2003;8:99–106
  13. Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 2001;37:1450–1457
  14. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108:1429–1437
  15. Laufs U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol. 2003;58:719–731
  16. Liu JL, Zucker IH. Regulation of sympathetic nerve activity in heart failure: a role for nitric oxide and angiotensin II. Circ Res. 1999;84:417–423
  17. Vejlstrup NG, Bouloumie A, Boesgaard S, et al. Inducible nitric oxide synthase (iNOS) in the human heart: expression and localization in congestive heart failure. J Mol Cell Cardiol. 1998;30:1215–1223
  18. Yildirir A, Muderrisoglu H. Non-lipid effects of statins: emerging new indications. Curr Vasc Pharmacol. 2004;2:309–318
  19. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?. Circ Res. 2001;89:201–210
  20. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail. 1996;2:243–249
  21. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001;103:2055–2059
  22. Kubota T, McTiernan CF, Frye CS, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res. 1997;81:627–635
  23. Ueland T, Yndestad A, Oie E, et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation. 2005;111:2461–2468
  24. Walsh MC, Choi Y. Biology of the TRANCE axis. Cytokine Growth Factor Rev. 2003;14:251–263
  25. Haramaki N, Ikeda H. Statins for heart failure: a potential for new treatment. Cardiovasc Res. 2003;60:217–219
  26. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001–1009
  27. Aronow WS, Ahn C. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol. 2002;90:147–149
  28. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997;3:249–254
  29. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582–1587
  30. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol. 2004;93:1124–1129
  31. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2002;18:220–228
  32. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation. 2005;112:357–363
  33. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol. 2004;43:642–648
  34. Hognestad A, Dickstein K, Myhre E, Snapinn S, Kjekshus J. OPTIMAAL Investigators. Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. Am J Cardiol. 2004;93:603–606
  35. Latini R, Anand I, Maggioni AP. Statins in symptomatic chronic systolic heart failure. A post hoc analysis of 5010 patients enrolled in Val-HeFT. [abstract] Eur Heart J. 2004;25:1473
  36. Krum H, Bailey M, Meyer W. Impact of statin therapy on clinical outcomes in CHF patients according to β-blocker use: results of CIBIS. [abstract] Eur Heart J. 2004;25:1474
  37. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-Term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003;108:839–843
  38. Laufs U, Wassmann S, Schackmann S, Heeschen C, Bohm M, Nickenig G. Beneficial effects of statins in patients with non-ischemic heart failure. Z Kardiol. 2004;93:103–108
  39. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet. 2000;356:930–933
  40. Bastiaanse EM, Atsma DE, Kuijpers MM, Van der Laarse A. The effect of sarcolemmal cholesterol content on intracellular calcium ion concentration in cultured cardiomyocytes. Arch Biochem Biophys. 1994;313:58–63
  41. Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med. 2000;132:636–640
  42. Soja AM, Mortensen SA. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol Aspects Med. 1997;18(Suppl):S159–S168
  43. Tavazzi L, Tognoni G, Franzosi MG, et al. GISSI-HF Investigators. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail. 2004;6:635–641
  44. Ashton E, Liew D, Krum H. Should patients with chronic heart failure be treated with “statin.”. Heart Failure Monitor. 2003;3:82–86
  45. Kjekshus J, Dunselman P, Blideskog M, et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics. Eur J Heart Fail. 2005;7:1059–1069

PII: S1071-9164(06)00063-7

doi: 10.1016/j.cardfail.2006.02.001

Journal of Cardiac Failure
Volume 12, Issue 6 , Pages 473-478 , August 2006

Article Tools

* Image Usage & Resolution